MA53688A1 - Anticorps monoclonaux qui se lient spécifiquement à trbv-9 de l'humain - Google Patents

Anticorps monoclonaux qui se lient spécifiquement à trbv-9 de l'humain

Info

Publication number
MA53688A1
MA53688A1 MA53688A MA53688A MA53688A1 MA 53688 A1 MA53688 A1 MA 53688A1 MA 53688 A MA53688 A MA 53688A MA 53688 A MA53688 A MA 53688A MA 53688 A1 MA53688 A1 MA 53688A1
Authority
MA
Morocco
Prior art keywords
antibody
human
monoclonal antibodies
trbv
specifically bind
Prior art date
Application number
MA53688A
Other languages
English (en)
Other versions
MA53688B1 (fr
Inventor
Timofey Aleksandrovich Nemankin
Roman Alekseevich Ivanov
Pavel Andreevich Iakovlev
Anna Konstantinovna Vladimirova
?Lga Vladimirovna Britanova
Mariia Aleksandrovna Shchemeleva
Alexey Konstantinovich Misorin
Dmitry Borisovich Staroverov
Anna Valentinovna Evstrateva
Arina Vitalevna Anikina
Dmitry Valentinovichvna Morozov
Sergey Anatolievichvna Lukyanov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2018146029A external-priority patent/RU2711871C3/ru
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of MA53688A1 publication Critical patent/MA53688A1/fr
Publication of MA53688B1 publication Critical patent/MA53688B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un anticorps monoclonal humanisé ou son fragment de liaison d'antigène qui se lient spécifiquement à la famille trbv-9 des récepteurs cellulaires t de l'humain. L'invention concerne également un acide nucléique codant pour cet anticorps ou un fragment de liaison à un antigène de celui-ci, un vecteur d'expression, un procédé de production d'un anticorps et l'utilisation d'un anticorps pour traiter des maladies ou des troubles associés à la famille des récepteurs des lymphocytes t humains. L'invention vise notamment la création d'anticorps qui peuvent être utilisés pour la thérapie, notamment lors d'une spondylarthrite ankylosante (sa ou maladie de bechterew), de la la maladie cœliaque et des maladies sanguines malignes dont la pathogenèse est liée à l'implication des récepteurs des cellules t trbv9.
MA53688A 2018-12-25 2019-12-24 Anticorps monoclonaux qui se lient spécifiquement à trbv-9 de l'humain MA53688B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2018146029A RU2711871C3 (ru) 2018-12-25 Моноклональные антитела, которые специфически связываются с участком бета цепи семейства TRBV-9 Т-клеточного рецептора человека, и способы их применения
PCT/RU2019/050257 WO2020139171A1 (fr) 2018-12-25 2019-12-24 Anticorps monoclonaux qui se lient spécifiquement à trbv-9 de l'humain

Publications (2)

Publication Number Publication Date
MA53688A1 true MA53688A1 (fr) 2022-06-30
MA53688B1 MA53688B1 (fr) 2023-03-31

Family

ID=69184146

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53688A MA53688B1 (fr) 2018-12-25 2019-12-24 Anticorps monoclonaux qui se lient spécifiquement à trbv-9 de l'humain

Country Status (25)

Country Link
US (1) US12297269B2 (fr)
EP (2) EP3904387B1 (fr)
JP (1) JP7507160B2 (fr)
KR (1) KR20210118843A (fr)
CN (1) CN113692412B (fr)
AR (1) AR117735A1 (fr)
AU (1) AU2019416787A1 (fr)
BR (1) BR112021012550A2 (fr)
CA (1) CA3124800A1 (fr)
CL (1) CL2021001704A1 (fr)
CO (1) CO2021008204A2 (fr)
CR (1) CR20210353A (fr)
EA (1) EA202100199A1 (fr)
EC (1) ECSP21046332A (fr)
IL (1) IL284367A (fr)
JO (1) JOP20210168B1 (fr)
MA (1) MA53688B1 (fr)
MX (1) MX2021007718A (fr)
MY (1) MY206214A (fr)
NZ (1) NZ778430A (fr)
PE (1) PE20211792A1 (fr)
PH (1) PH12021551535A1 (fr)
SG (1) SG11202106974SA (fr)
WO (1) WO2020139171A1 (fr)
ZA (1) ZA202104356B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2694412C9 (ru) * 2017-12-25 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Моноклональные антитела и способы их применения
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (fr) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Molécules multifonctionnelles se liant à calréticuline et utilisations associees
CA3105448A1 (fr) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Molecules d'anticorps anti-tcr et leurs utilisations
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
WO2025075529A1 (fr) * 2023-10-04 2025-04-10 Joint Stock Company "Biocad" Anticorps monoclonal ou fragment de liaison à l'antigène de celui-ci qui se lie spécifiquement au segment trbv5-1 du domaine variable de chaîne bêta du récepteur de lymphocytes t humains, et son utilisation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223426A (en) 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
US5766947A (en) 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
WO2010151416A1 (fr) 2009-06-25 2010-12-29 Fred Hutchinson Cancer Research Center Procédé de mesure de l'immunité adaptative
WO2012008397A1 (fr) 2010-07-12 2012-01-19 第一三共株式会社 Anticorps anti-epha2 et utilisation de celui-ci
US20130273089A1 (en) 2011-11-03 2013-10-17 Tolera Therapeutics, Inc. Antibody and methods for selective inhibition of t-cell responses
PL2991683T3 (pl) 2013-05-02 2020-03-31 Glykos Finland Oy Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem
EP3202784A1 (fr) * 2016-02-08 2017-08-09 Polybiocept AB Séquences de récepteurs de lymphocytes t pour une immunothérapie active
KR102436129B1 (ko) 2016-06-17 2022-08-26 메디진 이뮤노테라피스 게엠바하 T 세포 수용체 및 이의 용도
RU2019116312A (ru) 2016-11-14 2020-12-14 Фред Хатчинсон Кэнсер Рисерч Сентер Высокоаффинные tcr, специфичные к t-антигену полиомавируса клеток меркеля, и их применения
US20200040085A1 (en) * 2017-02-27 2020-02-06 Chugai Seiyaku Kabushiki Kaisha Anti-hla-dq2.5/8 antibody and its use for the treatment of celiac disease
CN107502671B (zh) * 2017-10-12 2020-05-05 中国医学科学院肿瘤医院 利用trbv家族成员预测曲妥珠单抗新辅助治疗乳腺癌患者疗效试剂盒及其应用
RU2694412C9 (ru) 2017-12-25 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Моноклональные антитела и способы их применения

Also Published As

Publication number Publication date
MA53688B1 (fr) 2023-03-31
WO2020139171A1 (fr) 2020-07-02
JP2022515820A (ja) 2022-02-22
CA3124800A1 (fr) 2020-07-02
ECSP21046332A (es) 2021-07-30
US12297269B2 (en) 2025-05-13
JOP20210168A1 (ar) 2023-01-30
NZ778430A (en) 2026-01-30
CN113692412A (zh) 2021-11-23
EP4721817A2 (fr) 2026-04-08
CN113692412B (zh) 2024-08-16
KR20210118843A (ko) 2021-10-01
MY206214A (en) 2024-12-04
EP3904387A4 (fr) 2022-09-07
US20220056133A1 (en) 2022-02-24
ZA202104356B (en) 2022-09-28
PH12021551535A1 (en) 2022-02-28
EP3904387B1 (fr) 2026-02-11
TW202033557A (zh) 2020-09-16
CR20210353A (es) 2021-12-20
EP3904387A1 (fr) 2021-11-03
JOP20210168B1 (ar) 2025-10-01
EA202100199A1 (ru) 2021-12-02
CL2021001704A1 (es) 2022-01-28
BR112021012550A2 (pt) 2021-09-14
PE20211792A1 (es) 2021-09-09
CO2021008204A2 (es) 2021-08-30
JP7507160B2 (ja) 2024-06-27
AR117735A1 (es) 2021-08-25
MX2021007718A (es) 2021-08-05
IL284367A (en) 2021-08-31
RU2711871C1 (ru) 2020-01-23
AU2019416787A1 (en) 2021-08-12
SG11202106974SA (en) 2021-07-29

Similar Documents

Publication Publication Date Title
MA53688A1 (fr) Anticorps monoclonaux qui se lient spécifiquement à trbv-9 de l'humain
MA53689A1 (fr) Anticorps humanisés contre un fragment bêta d'une chaîne de la famille 9 du récepteur cellulaire trbv-9 de l'humain et méthodes de leur application
MA50128B1 (fr) Anticorps monoclonaux liants le recepteur trbv9 des lymphocytes t et procédés de leur utilisation
AU2016292892B2 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
US10364286B2 (en) Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
MA31246B1 (fr) Anticorps antagoniste d'ox40, et leur utilisation dans le traitement de maladies inflammatoires et auto-immunes
JP7331168B2 (ja) 多発性骨髄腫におけるｍタンパク質反応の臨床評価
JOP20210265A1 (ar) الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها
CN111518205B (zh) 人源化抗Aβ单克隆抗体及其应用
JPS6312297A (ja) ヒトインタ−ロイキン−２−リセプタ−を認識するモノクロ−ナル抗体
MA44917B1 (fr) Anticorps ou son fragment de liaison d’antigènes apte a se lier au récepteur d'interleukine-6 de l'humain.
WO2024012434A1 (fr) Anticorps, fragment de liaison à l'antigène de celui-ci, et leur utilisation pharmaceutique
Suzuki et al. Idiotypic and fine specificity analysis of a (4‐hydroxy‐3‐nitrophenyl) acetyl (NP)‐specific suppressor T cell hybridoma at the level of cell surface structures, isolated receptor material and functional suppressor factor
Nishinarita et al. IgA isotype-restricted idiotypes associated with T15 Id+ PC antibodies.
JP7256172B2 (ja) ミニブタ試料において抗薬物抗体を決定するための方法
Ramberger et al. Synaptic autoimmunity: new insights into LGI1 antibody-mediated neuronal dysfunction
JP2017019755A (ja) 標識免疫複合体を用いたアレルギー反応迅速識別法およびその誘導試薬キット
WO2019031444A1 (fr) Procédé de mesure du taux d'occupation de substances de liaison spécifiques dans une population cellulaire
JP2009139372A (ja) ラットＩｇＥ測定試薬
OA18779A (en) Antibodies Specific for Hyperphosphorylated Tau and Methods of Use Thereof.